Lumen Apposing Metal Stent Market - Strategic Insights and Forecasts (2026-2031)

The Lumen Apposing Metal Stent market is forecast to grow at a CAGR of 5.9%, reaching USD 5.2 billion in 2031 from USD 3.9 billion in 2026.

The Lumen-Apposing Metal Stent (LAMS) market is experiencing consistent growth and development as a result of a broader trend toward less invasive techniques and a growing range of therapeutic uses of these devices. The main advantages of LAMS over traditional surgical methods are their ability to create secure lumen-to-lumen connections and achieve better clinical outcomes, reduced procedure time, and decreased complications through their design. As a result of these advantages, LAMSs are increasingly used as recovery times and hospital stays shorten. In addition, advances in technology and the expansion of available expertise for performing endoscopic ultrasound-guided procedures will help propel this market’s growth during the projected time period.

• By stent covering type, the market is segmented into fully covered LAMS and partially covered LAMS. Fully covered LAMS have the greatest market share because they provide a mechanism for preventing leakage and allow for easy removal following treatment. In addition, fully covered LAMS do not permit any new tissue to grow in the stent once it has been placed in its new position. Therefore, these stents are especially preferred for use in pancreatic and biliary drainage procedures when the interventions require some degree of controllability regarding the outcome of the surgery, as well as the health and well-being of the patient.

• By Delivery System, there are two types of delivery systems within the LAMS market: electrocautery-enhanced LAMS (EC-LAMS) and non-electrocautery LAMS. Since EC-LAMS have a single-step deployment procedure to create the stent, they continue to be adopted rapidly because they are a very efficient and effective means of performing advanced endoscopic interventions. The combination of puncturing, placing, and securing the stent during a single procedure reduces the complexity, time, and productivity necessary to perform these procedures.

• By Material, the LAMS market can be separated into nitinol-based stents and silicone-based stents. Nitinol has captured a majority share of the LAMS market due to its many applications and uses in the future.

• By application, the market is segmented into pancreatic fluid collections drainage, biliary and hepatobiliary drainage, gastrointestinal luminal strictures, and others. Pancreatic fluid collection drainage represents the leading application, as LAMS were initially designed for this purpose. Their large lumen diameter enables efficient drainage and supports direct endoscopic necrosectomy, improving treatment outcomes.

• By end user, the market is segmented into hospitals, speciality clinics, ambulatory surgical centres, and others. Hospitals dominate this segment due to the availability of advanced medical infrastructure and skilled professionals. These settings are preferred for complex endoscopic procedures, ensuring better patient monitoring, higher success rates, and comprehensive post-procedure care.

• Key market players in the lumen-apposing metal stent market include Boston Scientific Corporation, Olympus Corporation, Cook Medical, Taewoong Medical Co., Ltd., and M.I. Tech Co., Ltd. These companies are actively focused on advancing endoscopic stent technologies through innovative product offerings. For instance, Boston Scientific offers the AXIOS stent system, widely used in pancreatic fluid drainage, while Olympus and Taewoong Medical provide specialized gastrointestinal stents integrated with endoscopic platforms. Cook Medical and M.I. Tech are also strengthening their portfolios with minimally invasive stenting solutions, supporting broader clinical adoption across gastrointestinal and hepatobiliary applications.

Lumen-apposing metal stents (LAMS) are modern endoscopic devices used primarily to establish a stable and direct connection between two internal structures within the gastrointestinal tract (GI tract). The main purpose of LAMS is to allow the access and drainage of adjacent lumens, such as a fluid collection and the stomach or intestine, without requiring open surgery.

• LAMS have a short, saddle-shaped body with wide flanges on either end, which hold the stent in position and compress the two adjacent tissue walls together to minimize leakage and migration of the stent. By providing this type of stability, LAMS allow for the creation of a temporary anastomosis between the two luminal spaces to promote efficient drainage of fluids, pus, or necrotic tissue.

• LAMS are most commonly used for the drainage of pancreatic fluid collections, abscesses, or gallbladder infections in patients who are unable to undergo surgery. In addition to being used for drainage, LAMS can also be used under endoscopic ultrasound (EUS) guidance to insert a stent through the GI tract, wherein it expands and maintains its patency. The large internal diameter of LAMS allows for drainage of fluids as well as the passage of an endoscope for other potential therapeutic procedures, such as debridement.

• Recent clinical trials performed by the government demonstrate that LAMS are effective in promoting drainage and maintaining lumen patency over an extended period of time, and that LAMS serve as a minimally invasive means to provide therapeutic connectivity.

• This table presents key clinical epidemiology and intervention rates associated with acute pancreatitis, highlighting progression to pancreatic fluid collections and the proportion of cases requiring drainage. It defines the addressable patient population for lumen-apposing metal stents and supports market demand assessment by linking disease burden with procedural adoption trends.

Table: Clinical Epidemiology and Intervention Rates Supporting the LAMS Market’s Demand

Source: PMC, National Library of Medicine

Market Dynamics

Market Drivers

• Rising Prevalence of Gastrointestinal and Pancreatic Disorders

The increasing prevalence of pancreatic and gastrointestinal diseases is a major factor in the growth of the lumen opposing metal stent (LAMS) market, as these diseases require more innovative therapies. According to government-funded data from the National Institute of Diabetes and Digestive and Kidney Diseases, the rate of digestive diseases, such as pancreatitis, pancreatic cysts, and gastrointestinal obstructions, is rising due to ageing population, obesity, and lifestyle patterns.

• Patients with these types of disorders often develop complications such as fluid accumulation, strictures, and blockages requiring drainage or bypass solutions. Conventional surgical techniques tend to be invasive and come with significant risks, particularly in older adults or critically ill patients. Hence, there is a preference for minimally invasive endoscopic techniques where LAMSs are being used effectively.

• Consequently, the increasing burden of disease associated with gastrointestinal diseases will ultimately contribute to increased demand for advanced endoscopic devices and will remain a strong and sustainable driver for market growth.

• The National Cancer Institute estimates 67,440 new pancreatic cancer cases and 51,980 deaths in 2025, highlighting the aggressive nature and high mortality associated with this disease. This growing burden directly supports the demand for advanced, minimally invasive treatment options. Pancreatic cancer often leads to complications such as biliary obstruction and pancreatic fluid collections, which require effective drainage solutions. Lumen-apposing metal stents enable endoscopic management of these conditions, reducing the need for high-risk surgical procedures. As healthcare systems increasingly prioritize early intervention and patient-friendly treatments, rising incidence and mortality rates are strengthening the adoption of such stents, reinforcing disease prevalence as a key growth driver for this market.

Market Developments:

• January 2026: The U.S. Food and Drug Administration issued an early alert for Boston Scientific AXIOS stents, advising healthcare providers to cease use and return affected inventory to prevent risk during deployment.

• December 2025: Boston Scientific initiated a recall/removal of certain AXIOS™ LAMS and Electrocautery Enhanced Delivery Systems due to deployment and expansion issues, with a safety field notice and FDA alert issued across multiple markets

Market Segmentation

By End-User: Hospitals

By end user, the lumen-apposing metal stent market is segmented into hospitals, specialty clinics, ambulatory surgical centres, and others. Among end-users in the lumen-apposing metal stents market, hospitals hold the major share as they have the sophisticated healthcare infrastructure, advanced endoscopic equipment, and skilled gastroenterologists and interventional endoscopists. They handle many complicated gastrointestinal cases, including pancreatic fluid collections, biliary drainage, and other therapeutic procedures, which are the major applications of lumen-apposing metal stents (LAMS).

• There are 6,100 hospitals across the United States, of which 5,121 community hospitals play the main role in healthcare delivery.

• Additionally, there are 210 hospitals operated by the federal government for the military and veteran populations, while 656 non-federal psychiatric hospitals are mainly for mental health care.

• Moreover, 113 other hospitals provide specialized and niche healthcare services in various parts of the country.

• The U.S. Food and Drug Administration (FDA) regulations, European Medicines Agency (EMA) guidelines, and Central Drugs Standard Control Organization (CDSCO) policies are examples of government regulatory frameworks that fundamentally influence the lumen apposing metal stent market.

• These measures facilitate ensuring product safety, setting standard procedures for product approvals, and fostering product uptake through organized reimbursement and healthcare quality enhancement programs, among other methods.

• The continuous investments made in hospital-based endoscopy units, increased patient inflow, and the gradual awareness of minimally invasive procedures are factors leading the segment to steady growth.

• Hospitals usually play a major role in clinical research, training, and the use of new stent technologies first, which further enhances their role as the main end users in the global lumen apposing metal stent market.

Regional Analysis

Asia Pacific: China

The market for Lumen-Apposing Metal Stent (LAMS) in China is a rapidly expanding sector that operates within the larger gastrointestinal endoscopic devices and the pancreatic biliary stent market. The rising aging population, increasing disease burden due to lifestyle changes, and advancements in the healthcare system drive this growth.

• China has one of the world's largest and fastest-aging populations, which directly increases the demand for LAMS. The development of pancreatic disorders, gallstones, and biliary obstructions with subsequent drainage solutions occurs due to increasing age. With 280 million individuals aged 60 and older in 2022, China’s elderly population surpasses the total populations of most countries.

• The National Bureau of Statistics stated that 19.8% of the population reached 60 years or older in 2022, and this percentage will exceed 30% by 2035. This is expected to further rise to 28% by 2040, i.e., 402 million, according to the World Health Organization (WHO). In addition, China will become a super-aged society, with 20% of its population aged 65 years and older, and this process will take only 21 years. This same demographic transition took other ageing nations like Japan and Germany almost a century to achieve.

• Moreover, the Journal of Hepatology article stated that non-alcoholic fatty liver disease (NAFLD) has developed into a serious health crisis and keeps growing throughout China. The number of NAFLD cases reached more than 240 million affected individuals by 2016. The article also reported that China accounts for more than one-fifth of the world's NAFLD cases and has the majority of NAFLD cases reported in Asia. The modelling process predicts that the total number of NAFLD cases will rise to 314.58 million in China by 2030, representing the highest global disease growth rate. This growing burden is expected to boost market expansion.

• The combination of diverse lifestyle changes, which includes urbanization, western dietary patterns, rising obesity levels, diabetes, and alcohol consumption, rapidly boosts the risk of pancreatitis and other related health concerns in the country. These expanding conditions propel the need for LAMS in China.

North America: the US

The United States holds high growth potential for the lumen-apposing metal stent market, fuelled by ongoing developments in minimally invasive gastroenterology practices. This aims to offer better surgical alternatives than traditional stents that can be used in endoscopic ultrasound-guided procedures for draining pancreatic fluid collections (PFCs)

Likewise, the growing prevalence of IBD (Inflammatory Bowel Disorder), pancreatic cancers, and gastrointestinal disorders in the United States has accelerated the requirement for necessary treatment options with high positive results and recovery rate. According to the data provided by the American Cancer Society, in 2025, the estimated number of pancreatic cancer cases stood at 67,440, marking a 1.5% growth over the 2024’s estimated figure.

Hence, the lumen apposing metal stent has provided a new approach for fluid drainage during the treatment procedure of such disorders and with the prevalence rate showing constant progression, the demand is anticipated to witness an upward trajectory, thereby providing new growth prospects.

Additionally, technological innovations in clinical procedures have advanced significantly, providing easier deployment and thereby reducing procedural timings while improving overall efficiency. Research from multi-centres has shown that LAMS offers greater accuracy and a high success rate for draining pancreatic fluid collection (PFC) compared to traditional stents.

Hence, major companies such as Boston Scientific Corporation have been providing products, such as “Hot AXIOS Stent and Electrocautery-Enhanced Delivery System,” which are FDA-regulated and ideal for transduodenal endoscopic drainage of walled-off necrosis and gallbladder fluid in patients with acute cholecystitis. The ongoing transition towards minimally invasive endoscopic procedures, coupled with changes in demographics, is propelling the demand for new treatment options with superior outcomes, further contributing to the overall market expansion.

List of Companies

• Boston Scientific Corporation

• Mitra Industries Pvt. Ltd.

• Olympus Corporation

• Cook Medical Inc.

• M.I. Tech Co., Ltd.

• Micro-Tech Co., Ltd.

• Leufen Medical GmbH

• Taewoong Medical Co., Ltd.

Boston Scientific is a medical technology company that designs and produces less-invasive devices for the diagnosis and treatment of various medical conditions. Boston Scientific was established in 1979. Its headquarters is in Marlborough, Massachusetts.

The Boston Scientific Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System is a type of lumen-apposing metal stent (LAMS) specially designed to establish a safe, temporary, and spacious channel (anastomosis) between the digestive tract and the nearby fluid-filled cavities or organs. It is used with endoscopic ultrasound (EUS) support for the treatment of pancreatic pseudocysts, walled-off necrosis (WON), and gallbladder drainage.

Lumen-Apposing Metal Stent Market Scope: